证券代码：002980 证券简称：华盛昌 公告编号：2025-041 深圳市华盛昌科技实业股份有限公司 第三届监事会 2025 年第四次会议决议公告 本公司及公司全体监事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第三届监事会2025 年第四次会议通知于2025年10月20日以电子邮件方式发出，并于2025年10月25 日下午16:00以现场及通讯相结合在公司会议室召开。会议应出席监事3人，实际 出席监事3人，会议由监事会主席钟孝条先生主持。本次会议的召开，符合《中 华人民共和国公司法》《中华人民共和国证券法》的相关规定。 1、审议通过了《2025年第三季度报告》 经审核，监事会认为：董事会编制和审核深圳市华盛昌科技实业股份有限公 司2025年第三季度报告的程序符合法律、行政法规和中国证监会的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见公司在《证券时报》《中国证券报》《上海证券报》和巨潮资讯 网（www.cninfo.com. ...

证券代码：002980 证券简称：华盛昌 公告编号：2025-040 深圳市华盛昌科技实业股份有限公司 第三届董事会 2025 年第六次会议决议公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第三届董事会2025 年第六次会议通知于2025年10月20日以电子邮件、微信等方式发出，并于2025 年10月24日下午15:00以通讯方式召开。会议应出席董事8人，实际出席董事8人， 会议由董事长袁剑敏先生主持，公司监事及部分高级管理人员列席了会议。本次 会议的召开，符合《中华人民共和国公司法》《中华人民共和国证券法》的相关 规定。 二、董事会会议审议情况 2、《深圳市华盛昌科技实业股份有限公司第三届董事会审计委员会2025年 第三次会议会议决议》。 特此公告。 深圳市华盛昌科技实业股份有限公司 经与会董事充分讨论与表决，通过了以下议案： 1、审议通过了《2025年第三季度报告》 根据相关法律、法规、规范性文件的规定，公司编制了 2025 年第三季度报 告，具体内容详见公司在《证券时 ...

华盛昌公告，第三季度营收为1.81亿元，下降20.70%；净利润为2142.03万元，下降53.11%。前三季度 营收为5.3亿元，下降5.49%；净利润为6489.43万元，下降40.94%。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥180,616,496.69, a decrease of 20.70% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was ¥21,420,314.25, down 53.11% year-on-year[5] - The net profit for the first nine months of 2025 was approximately ¥64.89 million, a decrease of 40.94% compared to the same period last year[5] - The basic earnings per share for Q3 2025 was ¥0.11, reflecting a decline of 73.17% year-on-year[5] - The company's net profit for the current period is 64,106,611.60, a decrease of 41.9% compared to 110,500,763.73 in the previous period[24] - Operating profit decreased to 70,665,126.89, down 42.1% from 122,133,633.18 in the previous period[24] - The total comprehensive income for the current period is 65,764,920.65, compared to 108,917,546.46 in the previous period, indicating a decline of 39.6%[25] - Basic and diluted earnings per share decreased to 0.34 from 0.98, a decline of 65.3%[25] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥1,463,902,333.90, a decrease of 3.78% from the end of the previous year[5] - Total assets decreased to ¥1,463,902,333.90 from ¥1,521,375,238.03, reflecting a decline of 3.8%[21] - Total liabilities decreased to ¥381,975,961.78 from ¥423,355,772.72, a reduction of 9.8%[21] - Shareholders' equity totaled ¥1,081,926,372.12, down 1.1% from ¥1,098,019,465.31[21] - Long-term borrowings increased to ¥29,038,061.73, up 67.0% from ¥17,393,493.74[21] Cash Flow - Cash flow from operating activities for the first nine months of 2025 decreased by 48.80% to ¥76,430,471.31[11] - Cash flow from operating activities generated a net cash inflow of 76,430,471.31, down from 149,267,030.06, a decrease of 48.9%[27] - Cash and cash equivalents at the end of the period amounted to ¥360,552,605.88, an increase of 51.8% from ¥237,395,625.09 at the beginning of the period[19] - Cash and cash equivalents at the end of the period increased to 356,559,194.61, compared to 235,652,876.56 at the end of the previous period, an increase of 51.2%[27] - Investment activities generated a net cash flow of ¥156,736,782.37, a significant increase of 5999.99% due to the maturity of financial assets[11] - The company’s investment activities generated a net cash inflow of 156,736,782.37, a significant increase from 2,569,460.12 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,666[13] - Major shareholder Yuan Jianmin holds 53.22% of shares, totaling 100,800,000 shares[13] - The second-largest shareholder, Che Haixia, owns 7.39% of shares, amounting to 14,000,000 shares[13] - The company reported a total of 25,200,000 unrestricted shares held by major shareholders[14] - The company has a total of 478,000 shares held in its repurchase account, representing 0.25% of total shares[14] Management and Operations - Management expenses increased by 57.94% to ¥49,336,217.60, attributed to higher share-based payments and increased human resources投入[11] - The company incurred management expenses of 49,336,217.60, which is an increase from 31,237,016.51, reflecting a growth of 58%[24] - The company accelerated the construction of its production base in Vietnam in response to the US-China tariff escalation, achieving scale production within six months[6] - The net profit for September 2025, excluding share-based payment impacts, was ¥13.76 million, showing stability compared to ¥13.32 million in September 2024[6] Strategic Initiatives - The company has initiated the establishment of a joint venture with related parties, enhancing its investment strategy[18] - The "DeepSense" model has been approved for registration, indicating progress in new technology development[18] - The company has announced plans for foreign exchange hedging business[16] - The company is set to increase the cash management limit for idle self-owned funds[16] - The company plans to implement a 2024 employee stock ownership plan[14] - The company disclosed several important matters, including the completion of share repurchase and the use of raised funds for investment projects[16] Revenue and Costs - Total operating revenue for the period was ¥530,015,857.54, a decrease of 5.5% compared to ¥560,818,902.54 in the previous period[23] - Total operating costs increased to ¥459,018,401.79, up 4.7% from ¥438,206,698.09 in the previous period[23] - The company reported a total revenue from sales of goods and services of 652,761,634.66, an increase from 551,400,647.90, representing a growth of 18.3%[26] - Research and development expenses increased to 60,494,705.67, up from 55,827,768.93, reflecting a growth of 12%[24]

Core Viewpoint - The rise of AI smart glasses has attracted attention from both tech giants and traditional eyewear companies, with Huashengchang also entering this emerging market by developing its own AI products and models [1][6][9]. Company Developments - Huashengchang announced the development of its "DeepSense" model, which has passed generative AI service registration and will soon be available for internal testing [1]. - The company launched four AI medical devices at the 2025 China International Medical Equipment Expo, showcasing its commitment to integrating AI into healthcare solutions [6]. - Huashengchang has established a subsidiary focused on AI glasses, particularly for industrial applications, aiming to enhance measurement and detection efficiency [9]. Market Trends - The AI glasses market is rapidly growing, with a reported 145.5% year-on-year increase in shipments in Q2 2025, reaching 664,000 units in China [10]. - The Chinese AI glasses market is projected to have a compound annual growth rate of 56% over the next five years, supported by a robust supply chain for smart eyewear components [10][11]. - The overall market for smart glasses is expected to reach 4.153 million units sold by 2029, with a potential market size exceeding 100 billion yuan [12].

Core Viewpoint - The rapid development of AI glasses has attracted attention from both tech giants and traditional eyewear companies, with Huashengchang also entering this emerging market by leveraging its AI capabilities and existing expertise in measurement and medical devices [2][5]. Group 1: Company Developments - Huashengchang has announced the development of its "DeepSense" AI model, which has passed the generative AI service filing and will soon be available for internal testing [2]. - At the 2025 China International Medical Device Expo, Huashengchang showcased four AI medical devices powered by the DeepSense model, including a smart blood pressure monitor with an AI voice assistant [3]. - The company has a strategic focus on integrating AI into its measurement instruments and medical devices to enhance their core competitiveness [3][4]. Group 2: AI Glasses Market - Huashengchang established a subsidiary, Deep Mirror Technology, to focus on the development of AI glasses, particularly for industrial measurement applications [5]. - The AI glasses market is highly competitive, with many strong internet companies involved, but Huashengchang aims to differentiate itself by focusing on vertical applications rather than consumer products [5][6]. - The AI glasses market in China is projected to grow significantly, with a forecasted compound annual growth rate of 56% over the next five years, and a potential market size exceeding 100 billion yuan by 2029 [6][7].

Core Viewpoint - The rapid development of AI smart glasses has attracted attention from both tech giants and traditional eyewear companies, with Huashengchang also entering this emerging market by leveraging its AI capabilities and existing expertise in measurement and medical devices [1][4]. Group 1: Company Developments - Huashengchang has announced the development of its "DeepSense" AI model, which has passed the generative AI service filing and will soon be available for internal testing [1]. - The company showcased four AI medical devices at the 2025 China International Medical Device Expo, including a smart blood pressure monitor with an AI voice assistant, demonstrating its commitment to integrating AI into healthcare solutions [2]. - Huashengchang has a strategic focus on combining AI with measurement and sensor technologies, aiming to provide customized industrial measurement solutions [3]. Group 2: Market Trends - The AI glasses market in China is experiencing significant growth, with a reported shipment of 664,000 units in Q2 2025, marking a year-on-year increase of 145.5% [5]. - The market is projected to have a compound annual growth rate of 56% over the next five years, indicating a robust growth trajectory for AI glasses [5]. - The overall market for smart glasses is expected to reach 415.3 million units by 2029, with a potential market size exceeding 100 billion yuan [6]. Group 3: Competitive Landscape - Huashengchang's AI glasses are positioned to serve specific industrial applications rather than being mere consumer products, aiming to enhance operational efficiency and provide real-time data support for technicians [4]. - The company faces competition in a rapidly evolving market, where the integration of AI technology is crucial for maintaining a competitive edge [6].

Core Viewpoint - The company aims to redefine the value of measurement instruments through AI technology, emphasizing the importance of precise measurement in industrial and social operations [1] Group 1: Product Launch - Four AI-powered medical devices were launched, including a smart blood pressure monitor with an AI voice assistant, addressing common issues faced by elderly users [2] - The product lineup also includes a dual-level ventilator, a portable six-lead ECG device, and a combined blood pressure and ECG monitor, all designed to meet family health needs [2] Group 2: Technology and Innovation - The new products are positioned as health management tools rather than mere measurement devices, achieving medical-grade data accuracy through over 30 years of sensor technology and data analysis [3] - The DeepSense model, a generative AI service, has been officially registered and is designed to provide intelligent support and integrated solutions for measurement and detection industries [3][4] Group 3: Future Development - The company plans to leverage AI to reconstruct its entire product line, aiming to drive digital transformation in the measurement instrument industry [6] - A new subsidiary has been established to focus on AI upgrades, with plans to develop AI glasses tailored to user needs, enhancing measurement capabilities in various applications [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002980 证券简称：华盛昌 公告编号：2025-039 深圳市华盛昌科技实业股份有限公司 关于2024年限制性股票激励计划预留授予登记完成的公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1、预留授予日：2025年9月12日 6、股票来源：公司向激励对象定向发行本公司A股普通股。 根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交易所、中国证券登记结算有 限责任公司深圳分公司的有关规则，深圳市华盛昌科技实业股份有限公司（以下简称"公司"或"华盛 昌"）完成了2024年限制性股票激励计划（以下简称"本激励计划"）的预留授予登记工作，现将有关事 项公告如下： 一、已履行的相关审批程序 （一）2024年9月14日，公司第三届董事会2024年第八次会议审议通过了《关于公司〈2024年限制性股 票激励计划（草案）〉及其摘要的议案》、《关于公司〈2024年限制性股票激励计划实施考核管理办 法〉的议案》、《关于提请股东大会授权董事会办理2024年限制性股票激励计划相关事 ...

Group 1 - The company has completed the registration work for the reserved grant of the 2024 restricted stock incentive plan [2] - The listing date for the reserved grant of restricted stock is set for September 25, 2025 [2] - A total of 260,000 shares will be granted to 4 individuals at a price of 7.21 yuan per share (adjusted) [2]